Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Randomized Controlled Trial of Postmastectomy Hypofractionated Radiotherapy Versus Conventional Fractionated Radiotherapy in Breast Cancer Patients Undergoing Prosthetic Breast Reconstruction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
506 participants
Mar 27, 2026
INTERVENTIONAL
Conditions
Summary
This study investigates the safety and efficacy of hypofractionated radiotherapy (HFRT) versus conventional fractionated radiotherapy (CFRT) in breast cancer patients undergoing total mastectomy with prosthetic reconstruction. Study Design Population: Patients with high-risk breast cancer after mastectomy and immediate implant reconstruction. Intervention: HFRT Arm: 43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks). Control Arm: CFRT (50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks). Endpoints Primary: Reconstruction failure rate (e.g., implant removal, capsular contracture)
Eligibility
Inclusion Criteria9
- Female, aged 18-75 years
- Karnofsky Performance Status ≥60
- Histopathologically confirmed invasive breast adenocarcinoma
- Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins
- pT3 or N2-3 disease; or pT1-2N1
- No distant metastasis
- Completed standard neoadjuvant/adjuvant chemotherapy cycles
- ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy
- Signed informed consent
Exclusion Criteria10
- Prior radiotherapy to chest wall or nodal regions
- Pregnancy or lactation
- T4 stage disease
- Autologous breast reconstruction of the irradiated breast
- Pre-radiotherapy local/regional/distant metastasis
- Grade ≥3 implant-related adverse events irreversible before radiotherapy
- Bilateral breast cancer requiring bilateral radiotherapy
- Concurrent/secondary malignancy with disease-free interval <5 years \[except non-melanoma skin cancer, papillary/follicular thyroid cancer, or cervical carcinoma in situ\]
- Active collagen vascular disease, e.g., SLE, scleroderma
- Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07084519